Significance of Mutation Spots and Concurrent Gene Mutations on Prognosis and Clinical Outcomes in Myelodysplastic Syndromes With SF3B1 Mutation
Cancer Medicine · 2025-05 · 14 (9)
DOI: 10.1002/cam4.70930 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 08.05.2025. Verfasst von Qi Liu und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, RNA Splicing Factors, Mutation, Phosphoproteins. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The General Program of Shanghai Science and Technology Commission.
Abstract (Originalsprache)
Purpose
To investigate the clinical characteristics and prognosis of mutation spots and concomitant gene mutations in myelodysplastic syndromes (MDS) with SF3B1 mutation ( SF3B1 mut ). Patients and Methods Patients diagnosed with MDS at Shanghai Jiao Tong University School of Medicine Affiliated Sixth People's Hospital from October 2008 to November 2023 were enrolled in this study. SF3B1 mut was identified by next‐generation sequencing (NGS).
Results
One hundred and seven (8.7%) cases harbored the SF3B1 mutation. The most frequent SF3B1 mut , noted in 47.66% of all patients, was the hotspot K700E . K666 and R625 were observed in 24.30% and 9.35%, respectively. Two less frequent mutation subtypes accounted for 5.61% of H662 and 4.67% of E622 . Patients with the K666 mutation showed more severe thrombocytopenia ( p = 0.032), significantly lower NK cell percentage ( p = 0.001), and the Th1/Th2 ratio ( p = 0.018) in the bone marrow (BM). The overall survival (OS) in patients with E622 and H662 mutations was significantly longer than that of patients with the R625 mutation ( p = 0.045) and the K666 mutation ( p = 0.010). Multi‐variance analysis showed the SF3B1 mutation involving the K666 hotspot independently predicted overall survival in MDS (HR 2.094, p = 0.050). Notably, most (11/13, 84.6%) of concomitant TP53 mutations were mono‐hit, which did not affect the survival of patients in our cohort.
Conclusions
SF3B1 mut patients with specific mutation spots and concomitant gene mutations showed distinct clinical features and prognosis. Consequently, a comprehensive study of specific subtypes is of great significance for improving the prognosis of patients with SF3B1 mutations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Hematology, Shanghai Eighth People's Hospital, Shanghai, China.
ORCID-Profile: Qi Liu
Förderung
- The General Program of Shanghai Science and Technology Commission
Zitieren
APA
Liu, Q., Xu, F., Guo, J., Xu, F., Huang, X., Chen, J., Jin, J., Zhou, L., He, Q., Wu, D., Song, L., Zhang, Z., Guo, C., Su, J., Zhang, Y., Yan, M., Chang, C., Li, X., & Wu, L. (2025). Significance of Mutation Spots and Concurrent Gene Mutations on Prognosis and Clinical Outcomes in Myelodysplastic Syndromes With SF3B1 Mutation. Cancer Medicine, 14(9). https://doi.org/10.1002/cam4.70930
Vancouver
Liu Q, Xu F, Guo J, Xu F, Huang X, Chen J, et al. Significance of Mutation Spots and Concurrent Gene Mutations on Prognosis and Clinical Outcomes in Myelodysplastic Syndromes With SF3B1 Mutation. Cancer Medicine. 2025;14(9). doi:10.1002/cam4.70930
BibTeX
@article{Liu2025,
author = {Liu, Qi and Xu, Fanhuan and Guo, Juan and Xu, Feng and Huang, Xinhui and Chen, Jianan and Jin, Jiacheng and Zhou, Liyu and He, Qi and Wu, Dong and Song, Luxi and Zhang, Zheng and Guo, Cha and Su, Jiying and Zhang, Yumei and Yan, Meng and Chang, Chunkang and Li, Xiao and Wu, Lingyun},
title = {Significance of Mutation Spots and Concurrent Gene Mutations on Prognosis and Clinical Outcomes in Myelodysplastic Syndromes With SF3B1 Mutation},
journal = {Cancer Medicine},
year = {2025},
volume = {14},
number = {9},
doi = {10.1002/cam4.70930}
}
EUVIMED